The use of cholera oral vaccine for containment of the 2019 disease outbreak in Sudan

Nouh S. Mohamed*, Yousif Ali, Sanaa Abdalrahman, Ayman Ahmed, Emmanuel Edwar Siddig

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


A cholera outbreak in Blue Nile and Sennar states, south-eastern and southern Sudan, took place during September-December 2019. An outbreak surveillance sample collection was made. Vibrio cholerae O1 Ogawa was isolated from clinical samples of all confirmed 200 and 132 cases in Blue Nile state and Sennar state, respectively. The case fatality rate was higher in Blue Nile state, 4% compared with only 2.3% in Sennar state. The Euvichol-Plus oral cholera vaccine was rapidly deployed for the first time in Sudan to the most at-risk populations in the two affected states, 1 471 188 and 1 546 542 individuals in Sennar and Blue Nile states, respectively. The rapid deployment of cholera vaccines as the major prevention and control strategy was successful and helped greatly with the containment of this epidemic. In-depth genomics studies are crucial for understanding the disease dynamics in Sudan by identifying locally circulating strains of the bacteria and further improving prevention and control strategy by characterising the susceptibility and resistance of these locally circulating strains to currently used antibiotics.

Original languageEnglish
Pages (from-to)763-766
Number of pages4
JournalTransactions of the Royal Society of Tropical Medicine and Hygiene
Issue number9
Publication statusPublished - Sept 2022
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.


Dive into the research topics of 'The use of cholera oral vaccine for containment of the 2019 disease outbreak in Sudan'. Together they form a unique fingerprint.

Cite this